Published in Int J Pharm on August 28, 2002
Are Washington Circle performance measures associated with decreased criminal activity following treatment? J Subst Abuse Treat (2007) 1.59
Insect attack and wounding induce traumatic resin duct development and gene expression of (-)-pinene synthase in Sitka spruce. Plant Physiol (2003) 1.35
Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. J Biol Chem (2006) 1.21
Polymeric drug delivery of platinum-based anticancer agents. J Pharm Sci (2009) 1.13
On-demand controlled release of docetaxel from a battery-less MEMS drug delivery device. Lab Chip (2011) 1.09
Drug-eluting stents: factors governing local pharmacokinetics. Adv Drug Deliv Rev (2006) 1.08
Racial and ethnic differences in substance abuse treatment initiation and engagement. J Ethn Subst Abuse (2012) 0.99
Copolymer micelles and nanospheres with different in vitro stability demonstrate similar paclitaxel pharmacokinetics. Mol Pharm (2012) 0.97
The inhibition of collagenase induced degradation of collagen by the galloyl-containing polyphenols tannic acid, epigallocatechin gallate and epicatechin gallate. J Mater Sci Mater Med (2010) 0.93
Drug-eluting stents: a multidisciplinary success story. Adv Drug Deliv Rev (2006) 0.92
Methotrexate loaded poly(L-lactic acid) microspheres for intra-articular delivery of methotrexate to the joint. J Pharm Sci (2004) 0.91
A magnetically controlled MEMS device for drug delivery: design, fabrication, and testing. Lab Chip (2011) 0.91
In vitro chelating, cytotoxicity, and blood compatibility of degradable poly(ethylene glycol)-based macromolecular iron chelators. Biomaterials (2008) 0.90
Fusidic acid and rifampicin co-loaded PLGA nanofibers for the prevention of orthopedic implant associated infections. J Control Release (2013) 0.90
Paclitaxel loaded poly(L-lactic acid) (PLLA) microspheres. II. The effect of processing parameters on microsphere morphology and drug release kinetics. Int J Pharm (2004) 0.89
Pharmacokinetic study of methotrexate following intra-articular injection of methotrexate loaded poly(L-lactic acid) microspheres in rabbits. J Pharm Sci (2005) 0.88
Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck. J Drug Target (2005) 0.87
Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. Cancer Chemother Pharmacol (2005) 0.86
In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer. Clin Cancer Res (2011) 0.85
The use of tissue sealants to deliver antibiotics to an orthopaedic surgical site with a titanium implant. J Orthop Sci (2012) 0.84
Intra-articular drug delivery systems: Overcoming the shortcomings of joint disease therapy. Expert Opin Drug Deliv (2009) 0.84
Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer. BJU Int (2008) 0.84
Effects of continuous and pulsatile PTH treatments on rat bone marrow stromal cells. Biochem Biophys Res Commun (2009) 0.84
Phase separation behavior of fusidic acid and rifampicin in PLGA microspheres. Mol Pharm (2012) 0.83
An in vitro study of plasticized poly(lactic-co-glycolic acid) films as possible guided tissue regeneration membranes: material properties and drug release kinetics. J Biomed Mater Res A (2010) 0.83
Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU Int (2008) 0.83
Hyperbranched polymers for controlled release of cisplatin. Dalton Trans (2008) 0.83
Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer. BJU Int (2008) 0.83
A preliminary report on the effects of paclitaxel-impregnated stents on sheep nasal mucosa. Am J Rhinol (2004) 0.83
Characterization of perivascular poly(lactic-co-glycolic acid) films containing paclitaxel. Int J Pharm (2004) 0.83
Methoxypolyethylene glycol-block-polycaprolactone diblock copolymers reduce P-glycoprotein efflux in the absence of a membrane fluidization effect while stimulating P-glycoprotein ATPase activity. J Pharm Sci (2007) 0.82
PLGA and PHBV microsphere formulations and solid-state characterization: possible implications for local delivery of fusidic acid for the treatment and prevention of orthopaedic infections. Pharm Res (2009) 0.82
Paclitaxel-loaded crosslinked hyaluronic acid films for the prevention of postsurgical adhesions. Pharm Res (2002) 0.82
The differential in vitro and in vivo responses of bone marrow stromal cells on novel porous gelatin-alginate scaffolds. J Tissue Eng Regen Med (2009) 0.81
Nonsurgical treatment of retrograde peri-implantitis: a case report. Int J Oral Maxillofac Implants (2010) 0.81
The inhibition of angiogenesis by antisense oligonucleotides to clusterin. Angiogenesis (2005) 0.81
Increased accumulation of paclitaxel and doxorubicin in proliferating capillary cells and prostate cancer cells following ultrasound exposure. Ultrasonics (2011) 0.81
Determining the critical micelle concentration of a novel lipid-lowering agent, disodium ascorbyl phytostanyl phosphate (FM-VP4), using a fluorescence depolarization procedure. Drug Dev Ind Pharm (2004) 0.80
P-glycoprotein efflux inhibition by amphiphilic diblock copolymers: relationship between copolymer concentration and substrate hydrophobicity. Mol Pharm (2008) 0.80
The combined use of paclitaxel-loaded nanoparticles with a low-molecular-weight copolymer inhibitor of P-glycoprotein to overcome drug resistance. Int J Nanomedicine (2013) 0.80
The use of nanocrystalline cellulose for the binding and controlled release of drugs. Int J Nanomedicine (2011) 0.80
Clusterin antisense complexed with chitosan for controlled intratumoral delivery. Int J Pharm (2007) 0.80
The characterization of novel polymeric paste formulations for intratumoral delivery. Int J Pharm (2004) 0.79
Paclitaxel-loaded poly(L-lactic acid) microspheres 3: blending low and high molecular weight polymers to control morphology and drug release. Int J Pharm (2004) 0.79
Absorption, distribution, metabolism, and excretion of [¹⁴C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening. Drug Metab Dispos (2011) 0.79
Synthesis and characterization of carboxylic acid conjugated, hydrophobically derivatized, hyperbranched polyglycerols as nanoparticulate drug carriers for cisplatin. Biomacromolecules (2010) 0.79
In vitro and in vivo evaluation of intravesical docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols in an orthotopic model of bladder cancer. Biomacromolecules (2011) 0.78
Fabrication of robust hydrogel coatings on polydimethylsiloxane substrates using micropillar anchor structures with chemical surface modification. ACS Appl Mater Interfaces (2014) 0.78
The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors. Cancer Chemother Pharmacol (2007) 0.78
Use of fibrin sealants for the localized, controlled release of cefazolin. Can J Surg (2006) 0.78
The characterization of paclitaxel-loaded microspheres manufactured from blends of poly(lactic-co-glycolic acid) (PLGA) and low molecular weight diblock copolymers. Int J Pharm (2007) 0.78
Intra-articular treatment of inflammatory arthritis with microsphere formulations of methotrexate: pharmacokinetics and efficacy determination in antigen-induced arthritic rabbits. Inflamm Res (2009) 0.77
Increased accumulation and retention of micellar paclitaxel in drug-sensitive and P-glycoprotein-expressing cell lines following ultrasound exposure. Ultrasound Med Biol (2012) 0.77
Tissue uptake of docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and their effects on the morphology of the bladder urothelium. Biomaterials (2011) 0.77
Mixed molecular weight copolymer nanoparticles for the treatment of drug-resistant tumors: formulation development and cytotoxicity. J Pharm Sci (2014) 0.77
Calcium pyrophosphate dihydrate crystal-induced inhibition of neutrophil apoptosis: involvement of Bcl-2 family members. Inflamm Res (2009) 0.77
Calcium pyrophosphate dihydrate crystal associated induction of neutrophil activation and repression of TNF-alpha-induced apoptosis is mediated by the p38 MAP kinase. Cell Signal (2004) 0.77
Drug-eluting stents: an innovative multidisciplinary drug delivery platform. Adv Drug Deliv Rev (2006) 0.76
Same-single-cell analysis using the microfluidic biochip to reveal drug accumulation enhancement by an amphiphilic diblock copolymer drug formulation. Anal Bioanal Chem (2014) 0.76
Drug intercalation in layered double hydroxide clay: application in the development of a nanocomposite film for guided tissue regeneration. Int J Pharm (2011) 0.76
The application of layered double hydroxide clay (LDH)-poly(lactide-co-glycolic acid) (PLGA) film composites for the controlled release of antibiotics. J Mater Sci Mater Med (2012) 0.76
Unimolecular micelles based on hydrophobically derivatized hyperbranched polyglycerols: ligand binding properties. Biomacromolecules (2008) 0.75
Helmet use and brain injury in motorcyclists in Florence, South Carolina. J S C Med Assoc (2010) 0.75
New directions in dental education. Dent Today (2007) 0.75
The solid-state characterization of fusidic acid. Int J Pharm (2011) 0.75
Interdependence of drug substance physical properties and corresponding quality control strategy. J Pharm Sci (2011) 0.75
Controlled release of alendronate from polymeric films. J Biomater Sci Polym Ed (2009) 0.75
Gap mapping: a paradigm for aligning two sequences. Appl Bioinformatics (2003) 0.75
The effect of substituents on the phenyl portion of the imido ligand on the structure and properties of molybdenum(VI) imido complexes. Inorg Chem (2002) 0.75
Quality: Out of hours and up to scratch. Health Serv J (2011) 0.75
Amphiphilic dextran-graft-poly(epsilon-caprolactone) films for the controlled release of paclitaxel. Int J Pharm (2004) 0.75
Out of hours fears are falling on deaf ears. Interview by Daloni Carlisle. Health Serv J (2012) 0.75